Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

Biotechnology

Zai Lab

Samantha Du

Clark Gu

Philip Li

Andrew Zhu

Christine Chiou

Robert J. Brown

Yajing Chen

Rafael G. Amado

Peter Huang

Jonathan Wang

F. Ty Edmondson

James Yan

Josh Smiley

Ning Xu

The Clinical Operations Team at Zai Lab is responsible for overseeing the planning, execution, and management of clinical trials for the company’s diverse pipeline of therapeutic candidates. This team collaborates with cross-functional partners to ensure that studies are conducted efficiently, comply with regulatory standards, and meet timelines, ultimately supporting the development of innovative treatments in oncology, autoimmune, and infectious diseases for the China market.

Clinical Operations Team

R&D and Scientific Research Team

Leadership Team

��

Clinical Operations Team

About

Team members

Other teams at Zai Lab

R&D and Scientific Research Team

Leadership Team

��������

Clinical Operations Team

About

Team members

Other teams at Zai Lab

R&D and Scientific Research Team

Leadership Team

��